Phase III Results Position Selecta/Sobi’s SEL-212 As Tough Competition For Krystexxa In Gout
Executive Summary
Analysts pointed to SEL-212’s more favorable dosing and adverse event profile with fewer limitations that may harm compliance versus Krystexxa from Horizon, which is soon to be acquired by Amgen.
You may also be interested in...
Amgen To Enhance Rare Disease Franchise With $27.8bn Horizon Takeover
The US major has announced its biggest acquisition to date in the form of a takeover that should expand its rare disease franchise and stave off concerns about internal products facing biosimilar competition.
Selecta/Sobi Gout Drug Numerically, Not Significantly, Beat Krystexxa
Analysts have mixed opinions about whether a Phase IIb study of SEL-212, which Selecta recently licensed to Sobi, helps the drug’s commercial potential versus Horizon’s Krystexxa.
ASCO Preview: Five Top Late-Breakers To Watch For
AstraZeneca plans to unveil multiple major data packages, while Servier reveals much-anticipated results in glioma, and ImmunoGen and Novartis will present key pivotal data in women’s cancers.